| Literature DB >> 28480523 |
Ingrid Kindermann1, Sonja Maria Wedegärtner1, Felix Mahfoud1,2, Joachim Weil3, Nicole Brilakis4, Julia Ukena1, Sebastian Ewen1, Dominik Linz1, Martin Fahy4, Giuseppe Mancia5, Michael Böhm1.
Abstract
Renal denervation has been shown to reduce blood pressure in patients with uncontrolled hypertension, but less is known about its impact on quality of life. This analysis evaluated 12-month blood pressure and quality of life outcomes in 934 patients from the Global SYMPLICITY Registry who completed the EuroQoL five-dimensions three-level questionnaire (EQ-5D-3L). At baseline, 32% of patients reported anxiety/depression and 48% reported pain/discomfort. At 12 months (n=496), office and 24-hour ambulatory systolic blood pressure were reduced by 13.9±26.6 and 7.7±19.3 mm Hg, respectively, and 8% (P<.001) more patients reported no problems in anxiety/depression. Furthermore, numerically more patients reported no problems in pain/discomfort (4%, P=.08). Perceived health-related quality of life (visual analog scale) improved from baseline to 12 months (68±18 vs 73±17, P<.001), and the improvement was largest among patients with severe anxiety/depression at baseline (50±24 vs 64±22, P=.005 [n=32]). In this analysis, renal denervation was associated with a significant improvement in health-related quality of life, particularly anxiety/depression. ©2017 Wiley Periodicals, Inc.Entities:
Keywords: EQ-5D; anxiety; depression; quality of life; renal sympathetic denervation
Mesh:
Year: 2017 PMID: 28480523 PMCID: PMC8031037 DOI: 10.1111/jch.13007
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN: 1524-6175 Impact factor: 3.738